Tempest Therapeutics(TPST) - 2025 Q4 - Annual Results

Exhibit 99.1 Tempest Reports Year End 2025 Financial Results and Provides Business Update Completed strategic acquisition of dual-targeting CAR-T assets from Factor Bioscience Inc. Named Matt Angel, Ph.D., Chief Executive Officer & President Announced positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in patients with relapsed/refractory multiple myeloma (rrMM) Brisbane, CA, March 30, 2026 – Tempest Therapeutics, Inc. (Nasdaq: TPST) ("Tempest"), a clinical- stage biotechnology com ...